跳至主要内容
临床试验/NCT03387176
NCT03387176已完成不适用

Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker

NYU Langone Health1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2017年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
13
试验地点
1
主要终点
Change in disease activity measured by relapse rate

研究概览

简要总结

Elevated plasma zonulin levels, which are supportive of a diagnosis of CD (celiac disease) in children with gastrointestinal symptoms, may indicate patients with difficult-to-manage NS who will benefit from initiation of a GFD (gluten free diet). This pilot study will determine whether high plasma zonulin levels can be used as a screening tool to identify patients with NS (nephrotic syndrome) who are likely to demonstrate a beneficial response to a GFD. It will provide important information about the feasibility of testing the efficacy of a GFD for this condition and assist in the design and sample size calculation for a definitive trial to test the beneficial effect of this dietary intervention. Although NS is a rare condition in childhood, it is a chronic disease that can lead to short- and long-term disability especially in those with difficult-to-manage disease. There is an urgent need to develop safe and effective new therapies in this subgroup. This project may indicate the utility of a common dietary modification, a GFD, to treat these patients. The growing medical use of and greater access to gluten-free food items underscore the feasibility and timeliness of this approach.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
9 Months 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Steroid sensitive NS: complete remission of proteinuria in response to administration of a standard course of corticosteroids
  • Difficult-to-manage NS: disease that cannot be controlled without incurring intolerable side effects from currently available immunosuppressive agents, namely corticosteroids, calcineurin inhibitors, mycophenolate mofetil, or rituximab. Patients with biopsy-proven MCD or FSGS will be eligible as long as they have steroid sensitive disease. However, a renal biopsy will not be required for enrollment into the trial.

排除标准

  • Any patient diagnosed with nephrotic syndrome that is not considered steroid sensitive or frequently relapsing
  • Pre-existing celiac disease or gastro-intestinal disorder that precludes use of a GFD

结局指标

主要结局

Change in disease activity measured by relapse rate

时间窗: 12 Months

Response is defined as a ≥50%decrease in relapse rate

Change in disease activity measured by change in dosage of corticosteroids and immunosuppressive medications

时间窗: 12 Months

reduction by ≥1 drug in exposure to immunosuppressive medications in response to the GFD

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Efficacy of a Gluten-free Diet in Difficult to... | 临床试验